Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Technology incentives launched

WASHINGTON - Amid the uproar over the President's blast at drug prices, the Congress and the White House last week called for the implementation of targeted capital gains legislation supported by the biotech industry.

The legislation was introduced in the Senate by Dale Bumpers, D-Ark., and in the

Read the full 472 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE